An article recently published by This is Money singled out a handful of pharmaceutical companies including Motif Bio Plc (LON:MTFB) and Optibiotix Health plc (LON:OPTI) as good small cap ideas. The article points out that these companies are likely to benefit from Goldman Sachs economist Jim O’Neill findings on super-bug resistance. By taxing the big pharma’s smaller companies who find new cures could be rewarded in a proposal suggested by O’Neil.
We asked OptiBiotix Health Plc CEO Stephen OHara for his thoughts on the article: ‘ This article from This is Money identifies companies like OptiBiotix who are developing alternative treatments to alleviate the problem with ‘super-bugs’, which Lord O’Neil’s government report suggest could cause 10 million unnecessary deaths a year by 2050. OptiBiotix’s technology is an exciting advance on current treatments and works different to antibiotics in that in addition to stopping bacteria from growing, it prevents skin damage and prevents bacteria from reattaching, reducing the risk of infection with resistant superbugs. With the lack of current viable treatment options we believe this is an exciting opportunity for future growth’.
